Overview

  • Product name

    Anti-Ras antibody [EPR3255] (HRP)
    See all Ras primary antibodies
  • Description

    Rabbit monoclonal [EPR3255] to Ras (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide within Human Ras aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control

    • WB: HEK293 and SHSY-5Y whole cell lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab199557 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 22 kDa (predicted molecular weight: 22 kDa).

Target

  • Function

    Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in disease

    Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similarities

    Belongs to the small GTPase superfamily. Ras family.
  • Post-translational
    modifications

    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localization

    Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links

  • Alternative names

    • C BAS/HAS antibody
    • C HA RAS1 antibody
    • C-BAS/HAS antibody
    • c-H-ras antibody
    • C-HA-RAS1 antibody
    • CTLO antibody
    • GTPase HRas antibody
    • GTPase KRas antibody
    • GTPase NRas antibody
    • H ras antibody
    • H RASIDX antibody
    • H-Ras-1 antibody
    • H-RASIDX antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • HRAS antibody
    • HRAS1 antibody
    • K ras antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-RAS antibody
    • KRAS antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-RAS antibody
    • N-terminally processed antibody
    • NRAS antibody
    • NRAS1 antibody
    • p21ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    • v ras neuroblastoma RAS viral oncogene homolog antibody
    see all

Images

  • Anti-Ras antibody [EPR3255] (HRP) (ab199557) at 1/5000 dilution + HEK293 (Human embryonic kidney cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 22 kDa
    Observed band size: 22 kDa


    Exposure time: 90 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab199557 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

  • Anti-Ras antibody [EPR3255] (HRP) (ab199557) at 1/5000 dilution + SHSY-5Y (Human neuroblastoma cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 22 kDa
    Observed band size: 22 kDa


    Exposure time: 4 minutes


    This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab199557 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

This product has been referenced in:

  • Tang M  et al. Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice. Oncol Lett 17:1267-1273 (2019). Read more (PubMed: 30655894) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab199557.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up